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Abstract
Background: Because mitochondria play an essential role in energy metabolism, generation of reactive oxygen species
(ROS), and apoptosis, sequence variation in the mitochondrial genome has been postulated to be a contributing factor to
the etiology of multifactorial age-related diseases, including cancer. The aim of the present study was to compare the
frequencies of mitochondrial DNA (mtDNA) haplogroups as well as control region (CR) polymorphisms of patients with
malignant melanoma (n=351) versus those of healthy controls (n=1598) in Middle Europe.
Methodology and Principal Findings: Using primer extension analysis and DNA sequencing, we identified all nine major
European mitochondrial haplogroups and known CR polymorphisms. The frequencies of the major mitochondrial
haplogroups did not differ significantly between patients and control subjects, whereas the frequencies of the one another
linked CR polymorphisms A16183C, T16189C, C16192T, C16270T and T195C were significantly higher in patients with
melanoma compared to the controls. Regarding clinical characteristics of the patient cohort, none of the nine major
European haplogroups was associated with either Breslow thickness or distant metastasis. The CR polymorphisms A302CC-
insertion and T310C-insertion were significantly associated with mean Breslow thickness, whereas the CR polymorphism
T16519C was associated with metastasis.
Conclusions and Significance: Our results suggest that mtDNA variations could be involved in melanoma etiology and
pathogenesis, although the functional consequence of CR polymorphisms remains to be elucidated.
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Introduction
Malignant melanoma is one of the most aggressive skin cancers
arising from the pigment-producing cells called melanocytes. Due
to the fact that its worldwide incidence in Caucasian populations
has been rising steadily for several decades [1], malignant
melanoma has become an important public health issue and its
early detection remains vital to lowering mortality [2]. As in many
other malignancies, both genetic predisposition and environmental
risk factors such as UV radiation are involved in melanoma
development [1].
Mitochondria play an essential role in energy metabolism,
initiation of apoptosis and generation of reactive oxygen species
(ROS). Therefore, it has long been postulated that variation of
mitochondrial functions may contribute to the development and
progression of cancer [3].
Mitochondria possess their own DNA (mtDNA), a circular
double-stranded molecule consisting of 16,569 base pairs coding
for 37 genes: 13 protein subunits of the electron transport chain,
22 tRNAs and 2 rRNAs. In addition, mtDNA contains a non-
coding control region (CR), also called the D-loop, with regulatory
sequences controlling mtDNA replication and transcription [4].
The mutation rate of mtDNA is approximately 10-fold higher
than that of nuclear DNA. This is due to the absence of protecting
histones and the lack of an efficient DNA repair system in
mitochondria. Furthermore, the respiratory chain is a potent
source of free radicals, which additionally can lead to DNA
damage [3,5]. It has been hypothesized that mtDNA mutations or
inherited polymorphisms may alter the encoded protein subunits
of the respiratory chain complexes. This in turn could result in
altered ROS production, precipitating a cascade of events,
including elevated levels of mtDNA mutation, impairment of
respiratory chain activity, and further ROS generation, thus
setting in motion a vicious circle of oxidative stress, which may be
involved in the formation and progression of tumors [6,7,8].
Somatic mtDNA mutations have been found in several
malignancies, including breast, ovarian, endometrial, prostate,
colorectal, gastric, thyroid, renal, hepatocellular, esophageal,
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region (nucleotides 16024–516) has been shown to be a mutational
hot spot in human malignancies [13,14]. There is strong evidence
that genetic instability in the D-loop region may be involved in
carcinogenesis of human cancers, possibly by affecting copy
number and gene expression of the mitochondrial genome [15].
Mithani et al. reported finding somatic mitochondrial mutations
in melanoma specimens and melanoma cell lines, with an
incidence of 75% [16]; the incidence of mutations within the D-
loop region was considerably higher than for the remainder of the
mitochondrial genome. Another study detected somatic mito-
chondrial mutations in 45% of melanoma cell lines and 42% of
melanoma specimens [17]. Somatic alterations within the poly-
cytidine (poly-C) tract (nucleotides 303–315) of the D-loop region
were detected in 30% of melanoma cell lines and in 17% of
melanomas. Deichmann et al. found several alterations of the
mitochondrial D-loop in primary melanoma tumors; the overall
frequency was 12% [18]. This is in line with another melanoma
study, which detected an overall frequency of D-loop alterations of
13% [19].
Investigation of somatic mitochondrial mutations in cancer is
one approach to assess the contribution of mtDNA variation to
melanoma development and progression. The other approach is to
examine disease-associated mtDNA haplotypes and single-nucle-
otide polymorphisms (SNPs). There is evidence that ‘‘neutral’’
germ-line mtDNA polymorphisms may be risk factors for age-
related multifactorial diseases, including cancer, and that they may
influence disease outcome [20,21]. Association with mitochondrial
haplogroups has been discussed for prostate and renal cancer [22],
breast [21,23], thyroid [24], esophageal [25], endometrial [26]
and colorectal cancer [27].
The aim of the present study was to compare the frequencies of
mtDNA haplogroups and CR polymorphisms of patients with
malignant melanoma to those of healthy controls in Middle
Europe.
Results
The nine major European mtDNA haplogroups and CR
polymorphisms were analyzed in whole blood samples of 351
patients with malignant melanoma and compared to 1598 control
subjects [28]. Clinical characteristics of the patients and controls
are shown in Table 1.
MtDNA haplogroup distribution in patients with
malignant melanoma
The frequencies of the major European mitochondrial
haplogroups did not differ significantly between patients with
melanoma and control subjects (Table 2). Only the frequency of
haplogroup K was significantly lower in patients with malignant
melanoma (p=0.043), but the difference did not remain
statistically significant after adjustment for sex and age
(p=0.129).
CR polymorphisms in patients with malignant melanoma
The second part of our study focused on CR polymorphisms.
MtDNA was analyzed between nucleotide positions (np) 16024
and 526 in all 351 melanoma patients, and 211 homoplasmic
polymorphisms were found (Table S1). Among these polymor-
phisms, we detected 196 single base-pair exchanges, seven single
base-pair deletions and two single base-pair insertions, compared
to the revised Cambridge Reference Sequence. At position 302 we
found CC-insertions, and at position 310 TC-insertions in addition
to C-insertions. A CA-deletion at positions 514 and 515 occurred
24 times. CA-insertions, CACA-insertions and CACACA-inser-
tions at this site were observed 23 times. Of the 211
polymorphisms detected, 13 are not listed in MITOMAP or the
Human Mitochondrial Genome Database (www.mitomap.org;
www.genpat.uu.se/mtDB/). Twenty-six of the 211 CR polymor-
phisms were detected at a frequency $5% in either the melanoma
or the control group [29] (Table 3). These were subjected to
further statistical analysis. Five of them, A16183C, T16189C,
C16192T, C16270T and T195C, were highly linked to one
another and found to have a significantly higher frequency in
patients with melanoma compared to the control cohort (p,0.05)
(Table 3). These differences remained significant after adjustment
for sex and age.
Table 1. Characteristics of the study populations.
Patients with melanoma Controls
n=351 n=1598
Mean (SD
1) age (years) 59.2 (16.2) 51.7 (6.1)
Male (%) 49.0 63.9
Breslow thickness
#1.00 mm n=154 (43.9%) n.a.
1.01–2.00 mm n=89 (25.4%) n.a.
2.01–4.00 mm n=53 (15.1%) n.a.
.4.00 mm n=32 (9.1%) n.a.
missing n=23 (6.5%) n.a.
Metastasis
yes n=66 (18.8%) n.a.
no n=276 (78.6%) n.a.
missing n=9 (2.6%) n.a.
1SD: standard deviation.
n.a.: not applicable.
doi:10.1371/journal.pone.0027192.t001
Table 2. Frequencies (%) of Caucasian mitochondrial
haplogroups in cases and controls.
Haplogroup
Patients with
melanoma Controls p-Value
1
(n=351) (n=1598)
H 41.9 44.0 0.470
U 16.8 15.2 0.452
J 10.5 11.1 0.746
T 9.1 8.4 0.657
K 2.9 5.5 0.043
W 2.3 2.1 0.800
V 1.7 1.7 0.979
I 1.4 0.9 0.385
X 1.4 1.4 0.983
Others
2 12.0 9.7 0.202
1p-Value: Pearson chi-square or Fisher’s exact test.
2Haplogroups that could not be assigned to one of the nine major European
haplogroups.
doi:10.1371/journal.pone.0027192.t002
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To determine whether haplogroups or CR polymorphisms
within the melanoma cohort were associated with tumor
invasiveness or disease progression, we also analyzed the
frequencies of mtDNA haplogroups and CR polymorphisms in
relation to Breslow thickness of the tumor and metastasis.
The vertical depth of the melanoma (measured downward from
the top of the stratum granulosum of the epidermis) has been
shown to be the factor that best correlates with prognosis [2].
Several studies showed that Breslow thickness is associated with
male gender [30,31]. This finding was confirmed by our study.
Males (n=158) had a mean Breslow thickness of the tumor of
1.98 mm (SD 2.137) whereas females (n=170) showed a mean of
1.50 mm (SD 1.521) (p=0.032).
Logarithmized data of Breslow thickness were analyzed using a
two-sample unpaired t-test. None of the nine major European
haplogroups was found to be associated with Breslow thickness of
melanoma (data not shown). When subdividing melanoma cases
into categories for comparison of less invasive and thick melanoma
(category 1: Breslow thickness #4.00 mm, n=296; category 2
Breslow thickness .4.00 mm, n=32), haplogroup J was overrep-
resented among thick melanomas (21.9% versus 9.1%; p=0.034)
(Figure 1). This trend of higher incidence of haplogroup J within
Breslow category 2 was very similar in both sexes (data not shown).
In addition, the incidence of haplogroup H rose from 40.5%
(category 1) up to 53.1% (category 2) but did not reach statistical
significance.
When analyzing CR polymorphisms and logarithmized data of
Breslow thickness using a two-sample unpaired t-test, two
polymorphisms reached statistical significance. These two variants,
namely a CC-insertion at position 302 and a C-insertion at
position 310, are both located within a homopolymeric C-stretch
between np 303 and 315 interrupted by a thymine at position 310.
This poly-C stretch is situated in the second hypervariable region
(HVR II) and was reported to be a mutational hotspot [32].
Subjects harboring the A302CC-insertion (n=41) showed a
geometric mean Breslow thickness of 1.55 mm, whereas patients
without this alteration (n=287) had a geometric mean Breslow
Table 3. Frequencies (%) of CR polymorphisms higher than 5% in either patients with melanoma or controls and odds ratios (OR)
for the association between genetic variation and disease state.
mtDNA CR
polymorphisms
Frequency in
patients with
melanoma (%) n
1
Frequency in
controls (%) n
1 p-value
2 OR
3 (95%CI
4) p-value
5 OR (95%CI)
5
G16145A 5.1 18 4.3 68 0.471
A16183C 5.7 20 2.2 35 ,0.0005 2.70 (1.5–4.7) 0.0017 2.69 (1.4–5.0)
T16189C 16.8 59 11.9 190 0.012 1.50 (1.1–2.1) 0.045 1.42 (1.0–2.0)
C16192T 9.7 34 6.0 96 0.012 1.68 (1.1–2.5) 0.019 1.70 (1.1–2.6)
C16256T 7.7 27 6.1 98 0.280
C16270T 12.5 44 7.8 125 0.004 1.69 (1.2–2.4) 0.030 1.55 (1.0–2.3)
C16294T 10.0 35 9.1 146 0.625
T16304C 6.8 24 7.8 125 0.530
T16311C 10.3 36 13.8 221 0.073
T16362C 5.1 18 6.8 109 0.245
A16399G 6.0 21 4.2 67 0.144
T16519C 63.5 223 66.0 1055 0.375
A73G 54.7 192 54.3 867 0.879
T146C 10.3 36 9.2 147 0.539
C150T 11.1 39 11.3 180 0.935
T152C 23.6 83 22.7 363 0.707
G185A 6.3 22 5.7 91 0.677
T195C 21.9 77 17.1 273 0.032 1.36 (1.0–1.8) 0.043 1.37 (1.0–1.9)
T204C 5.1 18 4.3 68 0.471
G228A 6.8 24 6.1 97 0.589
C295T 10.5 37 10.3 165 0.904
A302C-Ins 39.6 139 38.2 610 0.618
A302CC-Ins 12.0 42 11.7 187 0.890
T310C-Ins 98.3 345 96.9 1548 0.149
C462T 8.0 28 8.3 133 0.831
T489C 12.3 43 11.5 184 0.697
1n: number of individuals with the respective polymorphism.
2p-value: derived from Pearson chi-square or Fisher’s exact test.
3OR: Odds Ratio.
4CI: Confidence Interval.
5adjusted for age and sex.
doi:10.1371/journal.pone.0027192.t003
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was associated with lower geometric mean Breslow thickess
(1.10 mm versus 3.06 mm; p=0.015). These two polymorphisms
also reached significance when compared within the two Breslow
category groups: 28.1% of patients in category 2 had the A302CC-
insertion compared to 10.8% in category 1 (p=0.002). The
frequency of the T310C-insertion was 99.0% in category 1 versus
90.6% in category 2 (p=0.020). In addition, the frequency of an A
to G transition at np 73 decreased from 56.1% in Breslow category
1 to 37.5% in category 2 (p=0.028) (Table 4).
Analyses of mitochondrial haplogroups and metastasis did not
reveal an association between specific haplogroups and tumor
invasiveness. Concerning CR polymorphisms, the T16519C
substitution was found in 48.5% of patients with metastases,
compared to 34.4% without metastases (p=0.026).
Discussion
Because mitochondria play a central role in energy and ROS
production, mtDNA is an obvious candidate for genetic
Figure 1. Frequencies (%) of mitochondrial haplogroups within different categories of Breslow thickness.
doi:10.1371/journal.pone.0027192.g001
Table 4. Frequencies (%) of the CR polymorphisms A73G, A302CC-Ins and T310C-Ins in Breslow categories 1 and 2.
CR polymorphism Frequency (%) in Breslow category 1 (#4.00 mm) Frequency (%) in Breslow category 2 (.4.00 mm) p-value
*
A73G 56.1 37.5 0.028
A302CC-Ins 10.8 28.1 0.002
T310C-Ins 99.0 90.6 0.020
*adjusted for age and sex.
doi:10.1371/journal.pone.0027192.t004
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time, frequencies of mtDNA haplogroups and CR polymorphisms
were determined in patients with malignant melanoma. No
significant difference between haplogroup frequencies of patients
with melanoma and control subjects could be found. Analysis of
clinical characteristics revealed that there is also no association
between mtDNA haplogroups and tumor invasiveness or meta-
static progression. Only when categorizing Breslow thickness did
we find an association: haplogroup J was overrepresented in thick
melanoma, indicating that this haplogroup might be associated
with higher tumor thickness and therefore less favorable prognosis
[2,33]. However, this finding must be considered as tentative given
the small sample size of patients within Breslow category 2.
Therefore, further investigations should examine a higher number
of melanoma cases with high values of Breslow thickness. In
addition, it has to be considered that we performed a high number
of statistical comparisons, which increases the possibility of
obtaining significant p-values by chance.
To our knowledge, this is the first association study on
melanoma and mitochondrial CR polymorphisms. To date,
mutations within the D-loop are of unclear relevance, but they
may influence the level of transcription and/or replication of the
mitochondrial genome [5].
In the present study, we evaluated CR germline polymorphisms
of the mtDNA of melanoma patients as possible risk factors for
melanoma formation and progression, taking into account
clinicopathological data.
The T16189C variant in the CR region has been associated
with several other multifactorial disorders [29,34,35], including
endometrial cancer [36]. The T to C substitution at position
16189 frequently generates an uninterrupted poly-C tract (np
16180–16195) in the D-loop. Furthermore, this variation often
leads to heteroplasmic length variation of the poly-C tract (.10
cytosines) in different mtDNA molecules of a single person [29,37].
When the T16189C polymorphism is accompanied by a second
nucleotide change, which is often the case at np 16192, the poly-C
is interrupted again. Liou et al. showed that different poly-C
variants showed differences in mean mtDNA copy numbers [38].
Subjects with an uninterrupted poly-C had the lowest mtDNA
copy number, whereas subjects harboring an interrupted poly-C
showed the highest mtDNA copy number. These findings support
an earlier assumption that the T16189C variant may affect
mtDNA replication [39] because np 16189 is very close to the
termination-associated sequence of the D-loop [40]. Within our
melanoma cohort, the variant with the interrupted poly-C showed
significantly elevated frequencies in melanoma cases compared to
controls (p=0.001). We assume that this variant may alter mean
mtDNA copy number also in melanoma cells. Concerning the
T195C and C16270T polymorphisms, it is unclear whether these
polymorphisms may be involved in tumor formation or disease
progression as there are, to our knowledge, no data available
showing their effect on mtDNA replication and transcription.
We further analyzed Breslow thickness of the tumor and
metastasis to determine whether a certain haplogroup or CR
polymorphism within the melanoma cohort correlates with tumor
invasiveness or disease progression. The A302CC-insertion, which
we found to be associated with a higher mean Breslow thickness,
and the T310C-insertion, which was related to lower mean
Breslow values, are both located within a poly-C stretch of HVR
II. This C-stretch is of interest because it is involved in the
formation of the persistent RNA-DNA hybrid that leads to the
initiation of mtDNA heavy-strand replication [41]. Therefore,
alterations of this region, in analogy to the T16189C variant,
might have an impact on transcription and replication of the
mitochondrial genome. The T16519C substitution was found at a
higher frequency in patients with malignant melanoma and
metastases, indicating a potential link to disease progression.
Previously, this polymorphism was found to be associated with
increased breast cancer risk [23] and with worse prognosis in
pancreatic cancer [42].
In conclusion we report for the first time an association of
mtDNA variations and malignant melanoma and its clinical
parameters, Breslow thickness and metastasis. Therefore, geneti-
cally determined variation in mitochondrial function has to be
considered, among other factors, as a potential contributor to
malignant melanoma development.
Methods
Ethics Statement
The study was conducted according to the Austrian Gene
Technology Act and complied with the Declaration of Helsinki.
All subjects gave written informed consent before entering the
study. The SAPHIR program was approved by the Local Province
of Salzburg Ethics Committee (‘‘Ethikkommission fu ¨r das Bundes-
land Salzburg; Amt der Salzburger Landesregierung, Abteilung 9
Gesundheit und Sport’’).
Patients and control subjects
Whole blood samples from 351 unrelated middle European
Caucasians with malignant melanoma were recruited at the
Department of Dermatology of the Paracelsus Medical University,
Salzburg, Austria from April 2007 until March 2010. Patients with
either melanoma in situ or melanoma in regression were excluded
from the study.
The control population consisted of 1598 unrelated individuals,
as previously described in detail [28], who were recruited for the
Salzburg Atherosclerosis Prevention Program (SAPHIR). The
mitochondrial haplogroup [43] and CR polymorphism [29] data
were obtained from previous studies.
DNA isolation and mitochondrial DNA analysis
DNA was extracted from whole blood samples either by a
modified salting out procedure as described by Miller et al. [44] or
by using a NucleoSpin Blood Kit (Macherey-Nagel, Du ¨ren,
Germany). A hierarchical system for mtDNA haplogrouping that
combines multiplex PCR amplification, multiplex single-base
primer extension, and capillary-based electrophoretic separation
was used to assess the most common European haplogroups (H, U,
J, T, K, I, V, W and X) as described in our pevious studies [45,46].
Haplogroups that could not be assigned to one of the nine major
European haplogroups by their single nucleotide polymorphism
(SNP) combination were designated as ‘‘others’’.
CR sequences were generated by direct DNA sequencing
between nucleotide positions 16024 and 526. Polymerase chain
reaction and sequencing was performed as described previously
[45]; however, a different forward primer (15997f: CACCAT-
TAGCACCCAAAGCT) was used. Data were analyzed with
Chromas software 1.56 (Technelysium, Tewantin, Australia) and
alignment was conducted with Blast 2 software (bl2seq) (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). The Cambridge Revised Se-
quence was used as a reference (GenBank accession number
J01415).
Statistical analysis
Frequencies of all mitochondrial haplogroups and CR poly-
morphisms were tested for independency from the disease using
Pearson chi-square statistics and Fisher’s exact test as appropriate.
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either the melanoma or the control group were subjected to
further statistical analysis. A p-value,0.05 was considered
statistically significant. Association of A16183C, T16189C,
C16192T, C16270T, and T195C with the disease state was
adjusted for sex and age by logistic regression analysis.
The clinical parameters mean Breslow thickness and metastasis were
analyzed within the melanoma cohort. Frequencies of all
mitochondrial haplogroups and CR polymorphisms were tested
for independency from the metastatic state using Pearson chi-
square statistics and Fisher’s exact test as appropriate. For
comparison of mean Breslow thickness between different hap-
logroups and CR polymorphisms, Breslow data were logarithmi-
cally transformed and analyzed using a two-sample unpaired t-test.
Adjustment for sex and age was conducted for A302CC-ins,
T310C-ins, A73G and T16519C using logistic regression analysis.
All analyses were performed using PASW 18.0 (SPSS GmbH,
Germany).
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